ANSES

Jeffs’ Brands Commences Sales of Its New Product Line Targeting The Bedbug Outbreak in France

Retrieved on: 
Vendredi, novembre 3, 2023
Jeff Brandes, Paris Olympics, Incidence, Paris, ANSES, Amazon Marketplace, Tourism

Tel Aviv, Israel, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that its brand of pest control solutions sold under the Fort Brand has launched its new product line targeting bedbug pest control on the Amazon Marketplace in France.

Key Points: 
  • The incidence of bedbug infestations in France has been increasing over the past few months, leading to a greater allocation of resources to address the issue, with the 2024 Paris Olympics games coming up in the summer of 2024.
  • According to ANSES, the French health and safety agency, more than one in ten households in France reported bedbug infestations between the years 2017 and 2022.
  • This rising concern extends to various settings, including hotel rooms, trains, and private residences, generating a growing demand for effective bedbug pest control solutions.
  • Our latest product line addresses a growing issue in our recently established market, France.

Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium

Retrieved on: 
Mercredi, janvier 4, 2023
Hospital, FAMHP, Food, Therapy, ANSES, Biophysical environment, SOFA, Immunotherapy, Occupational safety and health, Sepsis, Patient, Mortality, Medication, Safety, Manifest and latent functions and dysfunctions, Time-invariant system, Phase, Pharmaceutical industry

The Phase II trial is expected to include 80 to 160 patients across four cohorts, receiving varying doses of either AllocetraTM or a placebo, all in addition to standard-of-care therapy.

Key Points: 
  • The Phase II trial is expected to include 80 to 160 patients across four cohorts, receiving varying doses of either AllocetraTM or a placebo, all in addition to standard-of-care therapy.
  • The trial is supported by previously reported positive results from a Phase Ib investigator-initiated trial that showed vastly improved clinical outcomes, including SOFA scores, duration of hospitalization, and mortality, in AllocetraTM-treated sepsis patients, as compared to a group of matched historical controls who received standard-of-care therapy.
  • Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, “Expanding the study to France and Belgium with frozen formulation AllocetraTM is an important step in the execution of our ongoing Phase II sepsis trial.
  • We also believe that this is a notable regulatory achievement that provides additional validation for our amended study design and AllocetraTM frozen formulation.”

Health Canada approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Retrieved on: 
Mardi, mai 10, 2022
Alternative Medicine, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Laboratory, THC, EMA, ANSM, CBDA, FAMHP, Contract, API, FDA, GMP, ANSES, Tetrahydrocannabivarin, CBN, Cannabidivarin, PMDA, Cannabis Act, View, Health Canada, Seed, Life, CBD, Drug reference standard, Research, Eurofins Scientific, Fine chemical

Eurofins CDMO Alphora Inc. announces receipt in April 2022 of its Health Canada Standard Processing License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario Operations.

Key Points: 
  • Eurofins CDMO Alphora Inc. announces receipt in April 2022 of its Health Canada Standard Processing License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario Operations.
  • This is complementary to the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site.
  • Eurofins CDMO Alphora Inc. entered a licensing agreement with Kare Chemical Technologies Inc. in August 2021 for use of Kares innovative technology to synthetically produce high quality phytocannabinoids.
  • Eurofins CDMO Alphora Inc. has since developed scalable processes for several naturally occurring phytocannabinoids including CBD, CBDv, THC, THCv, and is preparing processes for others such as CBN, CBDA.

Eurofins CDMO Expands Spray Drying Capabilities

Retrieved on: 
Mardi, janvier 11, 2022
Biotechnology, Pharmaceutical, Health, PMDA, FAMHP, Contract, EMA, CDMO, Genomics, Life, Health Canada, Product-service system, Development, Spray drying, GMP, ANSES, View, Formulation, Solubility, Pharmacology, Food, Environment, FDA, Contract research organization, Laboratory, API, Active ingredient, ANSM, Fine chemical, Eurofins Scientific, Eurofins CDMO, Eurofins – the global leader in bio-analysis, EUROFINS CDMO, EUROFINS – THE GLOBAL LEADER IN BIO-ANALYSIS

Eurofins CDMO announces the expansion of existing Spray Dry Development & Production Services in North America.

Key Points: 
  • Eurofins CDMO announces the expansion of existing Spray Dry Development & Production Services in North America.
  • The Canadian facility, located in Mississauga, ON, has expanded its cGMP Spray Drying capabilities with the addition of a GEA Mobile Minor spray drying system and dedicated 500 sq.
  • With this expansion, Eurofins CDMO can further complement a broad range of services specializing in solubility enhancement for clinical development and small scale commercial programs.
  • The expansion of Spray Drying at Eurofins CDMO provides continued support of clinical development programs where formulation enabling is required for poorly soluble compounds.